8-K filing — CervoMed Inc. (CRVO)
Filed: 2026-10-14 AccNo: 0001437749-26-032620 Size: 168 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
CervoMed Shows Progress in Treating Rare Aphasia Condition
CervoMed reports a promising reduction in neuronal damage biomarkers during the first 12 weeks of its Phase 2a trial for neflamapimod.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CervoMed shares are trading lower after the company announced initial Phase 2a data showing reduced neurofilament light levels, a biomarker of neurodegeneration, following 12 weeks of neflamapimod treatment in nfvPPA patients.
CervoMed Announces Data From Its Phase 2a Clinical Study Of Nonfluent Variant Primary Progressive Aphasia Shows Reduction In Mean Plasma Levels Of Neurofilament Light Chain
CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company) announced initial data showing a reduction in mean plasma levels of neurofilament light chain (NfL), a key biomarker of neuronal damage and degeneration, over the